In studies on non-small cell lung cancer (NSCLC) cells resistant to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), NPS-1034 effectively overcame drug resistance and reduced the viabilities of drug-resistant cells in vitro via AXL or MET inhibition. Here, EGFR is linked to non-small cell lung carcinoma.